An integrative multi-omics analysis prioritized HEBP1 as a candidate mechanistic target and causal mediator for ischemic stroke risk. The study combined summary-data Mendelian randomization with HEIDI heterogeneity testing and colocalization, followed by validation in middle cerebral artery occlusion rat models. Single-cell sequencing localized higher HEBP1 expression to oligodendrocytes, and immune-metabolic analyses implicated pathways tied to complement activation and cholesterol homeostasis. Although the authors labeled chemical-docking findings (including phenobarbital) as hypothesis-generating, the convergence of computational and animal evidence elevates HEBP1 for follow-on target validation and therapeutic feasibility studies.
Get the Daily Brief